All In Biotech

Drug Trial Radar · NCT01929083

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

Influence of Progesterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Last checked: Nov 19, 2026Latest source record: Oct 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Apr 2013

Primary completion

Jun 2014

Study completion Jun 2014

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Heart Association
First posted
Aug 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 21 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Female sex is an independent risk factor for the potentially fatal drug-induced arrhythmia (irregular heartbeat) known as torsades de pointes (TdP), which is associated with prolongation of the corrected QT (QTc) interval on the electrocardiogram (ECG). Mechanisms for this increased risk in women are not well-understood. QTc interval duration has been shown to fluctuate throughout the phases of the menstrual cycle. Evidence indicates that the QTc interval response to drugs that may cause TdP is greater during the menses and ovulation phases of the menstrual cycle, during which serum progesterone concentrations are lowest, and lesser during the luteal phase, during which serum progesterone concentrations are highest. Additional evidence from our laboratory suggests that progesterone may be protective against TdP. Specific Aim 1: Establish the influence of oral progesterone administration as a preventive method by which to diminish the degree of drug-induced QT interval prolongation in women. Working hypothesis: Oral progesterone administration effectively attenuates enhanced drug-induced QT interval response in women. To test this hypothesis, progesterone or placebo will be administered in a crossover fashion to women during the menses phase of the menstrual cycle. QTc interval response to low-dose ibutilide, a drug known to lengthen the QT interval, will be assessed. The primary endpoint will be individually-corrected QT interval (QTcI) response to ibutilide, in the presence and absence of progesterone, which will be assessed by: 1) Effect on maximum change in QTcI, and 2) Area under the QTcI interval-time curves (AUEC). At the conclusion of this study, we will have established that oral progesterone administration is a safe and effective method of attenuating drug-induced QT interval prolongation.

Conditions

  • Prolonged QT Interval in EKG and Sudden Death

Interventions

  • ProgesteroneDrug

    Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

  • PlaceboDrug

    Subjects will receive oral placebo two capsules once daily every evening for 7 days

  • IbutilideDrug

    Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Baseline (Pre-Ibutilide) QTcI IntervalsTime frame: After 7 days of progesterone or placebo, prior to receiving IV ibutilide
  2. Maximum Individual-corrected QT Interval (QTcI)Time frame: 0, 15 & 30 minutes, and 1, 2, 4, 6, 8, and 12 hours post-ibutilide administration
  3. Maximum % Change From Baseline in QTcI Intervals Following Ibutilide AdministrationTime frame: After 7 days of progesterone or placebo
  4. Area Under the QTcI - Time Curve (AUEC)Time frame: From beginning of 10-minute ibutilide infusion to 1 hour following ibutilide infusion

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana Clinical Research Center

    Indianapolis, Indiana

  • Purdue University

    Indianapolis, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.